| Description | The introduction of Poly A tail at the 3'end of mRNA by tailing enzyme can increase the stability of mRNA and increase the efficiency of mRNA translation. The advantage of using the tailing enzyme to introduce the Poly A tail is that it is simple and easy to implement, avoiding the instability of The introduction of Poly A tail at the 3'end of mRNA by tailing enzyme can increase the stability of mRNA and increase the efficiency of mRNA translation. The advantage of using the tailing enzyme to introduce the Poly A tail is that it is simple and easy to implement, avoiding the instability of the plasmid caused by the introduction of too many consecutive T bases during plasmid construction.E. coli Poly (A) Polymerase does not rely on the presence of a template, and can catalyze the incorporation of ATP into the 3´ end of RNA in the form of AMP, that is, a poly A tail is added to the 3´ end of RNA. Poly (A) polymerase has a high tailing efficiency and can add 20~200 A bases to the 3´ end of RNA. Poly (A) structure helps to improve the translation efficiency of mRNA.This product is expressed in large-scale fermentation using Escherichia coli, is produced with medicinal specifications of raw materials, and strictly controls host protein residues, nucleic acid residues, etc., and conforms to GMP standard product production and quality management procedures to ensure that the production process and all raw materials can be traced.Quality requirements Project Standard Method Exterior Clear liquid Visual inspection Visible foreign body Compliance Chinese Pharmacopoeia 2020 Edition Fourth Part 1 Lamp Inspection Method (General Rule 0904) pH value 7.0-8.0 Chinese Pharmacopoeia 2020 Edition Part IV pH Determination Method (General Principle 0631) Active 4.9KUml-5.1KU/ml Tailing modification and efficiency determination method Purity ≥95% Chinese Pharmacopoeia 2020 Edition Part IV High Performance Liquid Chromatography (General Principle 0512) Endonuclease residue 004-DNA degradation does not exceed 10% Incubate SU enzyme with 004-DNA.37C for 3h Exonuclease residue 019 HindⅢ-DNA degradation does not exceed 10% Incubate SU enzyme with 019 HindⅢ-DNA at 37°C for 3h RNase residue Degradation of 293-RNA does not exceed 10% 5U enzyme and 293-RNA. Incubate at 37°C for 1h Bacterial endotoxin content ≤10 EU/mg Chinese Pharmacopoeia 2020 Edition Fourth Gel Limit Test Method (General Rule 1143) Host DNA residue ≤100 pg/mg Fluorescence quantitative PCR Host protein residue ≤50 ppm Chinese Pharmacopoeia 2020 Edition Part IV Method for the Determination of Bacterial Protein Residues (General Rule 3412) Mycoplasma Feminine Mycoplasma detection kit Heavy metal residue ≤10 ppm Chinese Pharmacopoeia 2020 Edition Fourth Heavy Metal Inspection Method (General Principle 0821) Follow the following specifications for production1. ISO 9001:2015, certified facility.2. "GMP Appendix-Cell Therapy Products" State Drug Administration.3. "General Introduction to Human Gene Therapy-Chinese Pharmacopoeia 2020" National Pharmacopoeia Commission.4. USP Chapter <1043>, Ancillary Materials for Cell, Gene, and Tissue-Engineered Products are used as excipients in cell therapy, gene therapy and tissue engineering products.5. USP Chapter <92>, Growth Factors and Cytokines Used in Cell Therapy Manufacturing Cytokines and growth factors used in the production of cell therapy products.6.Ph. Eur. General Chapter 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.Product Usage1. Used for RNA 3´ end labeling.2. Add Poly(A) tail to RNA for cloning or affinity purification. For example, adding Poly (A) to miRNA provides an oligo-dT primer binding site for cDNA synthesis.3. Improve the translation efficiency of RNA in eukaryotic cells.Preservation system20mM Tris-HCl; 300mM NaCl; 1mM DTT; 1mM EDTA; 0.1% TritonX-100; 50% (v/v) Glycerol, pH 7.5.ApplicationsThe intact mRNA expresses GFP protein in the cell, the capping enzyme is compared with the cap analogPrecautions1. Thermal inactivation conditions: 65°C, 20 min.2. The enzyme can only use RNA as a substrate.3. The enzyme adds AMP to the 3´ end of RNA with high selectivity, and does not add the same length of Poly (A) to all RNA molecules.4. The enzyme uses M-MuLV reverse transcriptase reaction buffer, which can also be used for reaction.5. The enzyme requires divalent cations such as Mg2+ to be active.6. The length of RNA plus A tail is affected by the amount of enzyme, ATP, reaction time and other factors. The amount of A required for different experiments will be different. The length of A can be adjusted by reducing the reaction time. The enzyme is at 37°C. About 30 A bases can be added in 30 minutes of reaction, and about 100 A bases can be added in 1 hour.7. EDTA inhibits the enzyme activity. If the reaction is stopped, it can be purified directly by adding EDTA to a final concentration of 10mM... Read More | Inquire | Inquire | Purity> 95% by SDS-PAGE and HPLC analyses.FunctionGrowth factor that controls proliferation and cellular differentiation in the retina and bone formation. Plays a key role in regulating apoptosis during retinal development. Establishes dorsal-ventral positional information in the retina and Purity> 95% by SDS-PAGE and HPLC analyses.FunctionGrowth factor that controls proliferation and cellular differentiation in the retina and bone formation. Plays a key role in regulating apoptosis during retinal development. Establishes dorsal-ventral positional information in the retina and controls the formation of the retinotectal map (PubMed:23307924). Required for normal formation of bones and joints in the limbs, skull, digits and axial skeleton. Plays a key role in establishing boundaries between skeletal elements during development. Regulation of GDF6 expression seems to be a mechanism for evolving species-specific changes in skeletal strucutres. Seems to positively regulates differentiation of chondrogenic tissue through the growth factor receptors subunits BMPR1A, BMPR1B, BMPR2 and ACVR2A, leading to the activation of SMAD1-SMAD5-SMAD8 complex. The regulation of chondrogenic differentiation is inhibited by NOG (PubMed:26643732). Also involved in the induction of adipogenesis from mesenchymal stem cells. This mechanism acts through the growth factor receptors subunits BMPR1A, BMPR2 and ACVR2A and the activation of SMAD1-SMAD5-SMAD8 complex and MAPK14/p38... Read More | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： 100B, previously called S100 beta, belongs to the S100 family within the EF-hand superfamily of Ca2+ binding proteins. S100 proteins contain two EF-hand motifs that differ in affinity, separated by a hingePurity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： 100B, previously called S100 beta, belongs to the S100 family within the EF-hand superfamily of Ca2+ binding proteins. S100 proteins contain two EF-hand motifs that differ in affinity, separated by a hinge region with a hydrophobic cleft that is exposed upon Ca2+ binding. S100B is a 91 amino acid (aa) protein, after removal of the initial methionine, and is found as homodimers of 10.4 kDa monomers. Human S100B shares 99%, 98%, 100%, 99% and 97% aa sequence identity with mouse, rat, rabbit, equine and bovine S100B, respectively. Within the S100 family, human S100B shows the highest aa identity (59%) with S100A1. S100B is expressed primarily by astrocytes and oligodendrocytes in the central nervous system, and by Schwann cells in the peripheral nervous system. Ca2+-bound S100B interacts in vitro with at least 20 cytoplasmic proteins, including several structural molecules such as tubulin and GFAP. It can inhibit the phosphorylation of these kinase substrates and others such as tau and neuromodulin. Astrocytes can secrete S100B, which then acts in a cytokine-like manner. Nanomolar concentrations of S100B are secreted constitutively, promote proliferation, and are neurotrophic and anti-apoptotic. Blood levels of S100B reflect extracellular concentrations within the nervous system, and are elevated in Down’s syndrome, Alzheimer’s disease and Tourette’s syndrome, metabolic stress, acute brain injury and brain tumors. Micromolar concentrations of S100B can be destructive and pro-apoptotic; they induce the expression of iNOS, COX-2, IL-1, IL‑6 and TNF-alpha by microglia, astrocytes or neurons. Most extracellular actions of S100B can be mediated by RAGE (receptor for advanced glycation end products), which is also a receptor for other S100 proteins... Read More |